| Field | Specification |
|---|---|
| Mfr No | |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Eltrekibart (HY553016) is a research-grade recombinant antibody targeting CXCL1. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG4, kappa |
| Target | CXCL1, GROA, GRO1, Neutrophil-activating protein 3, GRO, C-X-C motif chemokine 1, NAP-3, Growth-regulated alpha protein, MGSA, SCYB1, Melanoma growth stimulatory activity, GRO-alpha(1-73), GROB, CXCL2, Growth-regulated protein beta, Macrophage inflammatory protein 2-alpha, SCYB2, HSF, Gro-beta, Hematopoietic synergistic factor, MIP2-alpha, C-X-C motif chemokine 2, MIP2A, GRO2, SB-251353, GRO-beta-T, GRO3, CXCL3, GRO-gamma, Macrophage inflammatory protein 2-beta, GRO-gamma(1-73), C-X-C motif chemokine 3, GROG, Growth-regulated protein gamma, MIP2-beta, SCYB3, C-X-C motif chemokine 5, ENA-78(1-78), Neutrophil-activating peptide ENA-78, ENA78, SCYB5, Small-inducible cytokine B5, CXCL5, Epithelial-derived neutrophil-activating protein 78, C-X-C motif chemokine 6, SCYB6, Small-inducible cytokine B6, CXCL6, CKA-3, Chemokine alpha 3, Granulocyte chemotactic protein 2, GCP2, GCP-2, NAP-2, NAP-2(1-63), NAP-2(73), PPBP, CXCL7, PBP, Small-inducible cytokine B7, Macrophage-derived growth factor, LA-PF4, Leukocyte-derived growth factor, CTAP-III, CTAP-III(1-81), Low-affinity platelet factor IV, TGB1, Beta-TG, C-X-C motif chemokine 7, MDGF, Platelet basic protein, LDGF, NAP-2(74), THBGB1, NAP-2(1-66), CTAP3, SCYB7, GCP/IL-8 protein II, MDNCF, IL8/NAP1 form III, IL-8(1-77), Neutrophil-activating factor, GCP/IL-8 protein I, GCP/IL-8 protein VI, Interleukin-8, Chemokine (C-X-C motif) ligand 8, Neutrophil-activating protein 1, Monocyte-derived neutrophil chemotactic factor, (Ser-IL-8)72, MDNCF-b, LYNAP, GCP/IL-8 protein V, IL8/NAP1 form IV, MONAP, IL8/NAP1 form V, IL8/NAP1 form VI, NAP-1, Granulocyte chemotactic protein 1, GCP/IL-8 protein III, IL8/NAP1 form II, IL8, IL-8, CXCL8, IL8/NAP1 form I, (Ala-IL-8)77, Protein 3-10C, GCP/IL-8 protein IV, Emoctakin, GCP-1, C-X-C motif chemokine 8, NAF, T-cell chemotactic factor, MDNCF-c, Monocyte-derived neutrophil-activating peptide, Lymphocyte-derived neutrophil-activating factor |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P09341, P19875, P19876, P42830, P80162, P02775, P10145 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Growth-regulated alpha protein (CXCL1/2) is a ~11 kDa protein. Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity.
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
